Completed
PHASE1
INTERVENTIONAL
NCT03841630
A Safety Study of LY3437943 Given as a Single Injection in Healthy Participants
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This study is being conducted to determine the side effects related to LY3437943 given as a single injection under the skin to healthy participants. Blood tests will be performed to check how much LY3437943 gets into the bloodstream and how long the body takes to get rid of it. Each enrolled participant will receive a single dose of LY3437943 or placebo. The study will last up to approximately 71 days for each participant, including screening.
Interventions
Name:
LY3437943
Type:
DRUG
Description:
Administered subcutaneously (SC)
Name:
Placebo
Type:
DRUG
Description:
Administered SC
Primary Outcomes
Measure:
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
TimeFrame:
Baseline through final follow-up at approximately Day 43
Description:
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
Trial Information
NCT ID
NCT03841630
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE1
Sponsor
Eli Lilly and Company
Last Updated
December 15, 2025